TP53-EGFR共突变对非小细胞肺癌预后及治疗的研究进展

doi:10.11904/j.issn.1002-3070.2023.03.011

摘要/Abstract

摘要： 非小细胞肺癌(Non-small cell lung cancer,NSCLC)是全球癌症相关死亡的主要原因。表皮生长因子受体酪氨酸激酶抑制剂(Epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)是目前NSCLC患者靶向表皮生长因子受体(Epidermal growth factor receptor,EGFR)突变的标准一线治疗方法,然而原发性或获得性耐药会导致治疗中断和疾病进展。TP53突变是EGFR突变型NSCLC患者中最常见的共突变,研究表明TP53-EGFR共突变提示患者预后不良,对这类突变患者的治疗方案尚未达成共识。本文就TP53突变在晚期EGFR突变型NSCLC患者中的预后价值和TP53-EGFR共突变晚期NSCLC患者治疗的研究进展进行综述。

关键词: 非小细胞肺癌, TP53-表皮生长因子受体共突变, 预后, 治疗

Abstract: Non-small cell lung cancer(NSCLC)is the main cause of cancer-related deaths worldwide.Epidermal growth factor receptor tyrosine kinase inhibitor(EGFR-TKI)is a standard first-line treatment for targeting epidermal growth factor receptor(EGFR)mutations in NSCLC patients.However,primary or acquired drug resistance leads to treatment interruption and disease progression.TP53 mutation is the most common type of co-mutation in patients with EGFR-mutant NSCLC.Many studies have shown that TP53-EGFR co-mutation indicates a poor prognosis for patients,and there is no consensus on treatment plan for patients with such mutations.This article reviews the prognostic value of TP53 mutation in patients with advanced EGFR-mutant NSCLC and the research progress of TP53-EGFR co-mutation in patients with advanced NSCLC.

Key words: Non-small cell lung cancer, TP53 Epidermal growth factor receptor co-mutation, Prognosis, Treatment

中图分类号:

R734.2

陈琪, 何明旭, 贾科良, 苗健龙, 韩丽萍. TP53-EGFR共突变对非小细胞肺癌预后及治疗的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 262-266.

CHEN Qi, HE Mingxv, JIA Keliang, MIAO Jianlong, HAN Liping. Research progress on the prognosis and treatment of non-small cell lung cancer with TP53-EGFR co-mutation[J]. Journal of Practical Oncology, 2023, 37(3): 262-266.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.03.011

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I3/262

参考文献

1 Sung H,Ferlay J,Siegel RL,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
2 Chen P,Liu Y,Wen Y,et al.Non-small cell lung cancer in China[J].Cancer Commun(Lond),2022,42(10):937-970.
3 Fu K,Xie F,Wang F,et al.Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance[J].J Hematol Oncol,2022,15(1):173.
4 Johnson M,Garassino MC,Mok T,et al.Treatment strategies and outcomes for patients with EGFR-mutant non-small cell lung cancer resistant to EGFR tyrosine kinase inhibitors:Focus on novel therapies[J].Lung Cancer,2022,170:41-51.
5 Canale M,Andrikou K,Priano I,et al.The role of TP53 mutations in EGFR-mutated non-small-cell lung cancer:clinical significance and implications for therapy[J].Cancers(Basel),2022,14(5):1143.
6 Roeper J,Christopoulos P,Falk M,et al.TP53 co-mutations as an independent prognostic factor in 2nd and further line therapy-EGFR mutated non-small cell lung cancer IV patients treated with osimertinib[J].Transl Lung Cancer Res,2022,11(1):4-13.
7 Liu S,Yu J,Zhang H,et al.TP53 co-mutations in advanced EGFR-mutated non-small cell lung cancer:prognosis and therapeutic strategy for cancer therapy[J].Front Oncol,2022,12:860563.
8 Fan Z,Zhang Q,Feng L,et al.Genomic landscape and prognosis of patients with TP53-mutated non-small cell lung cancer[J].Ann Transl Med,2022,10(4):188.
9 Kennedy MC,Lowe SW.Mutant p53:it′s not all one and the same[J].Cell Death Differ,2022,29(5):983-987.
10 Vaddavalli PL,Schumacher B.The p53 network:cellular and systemic DNA damage responses in cancer and aging[J].Trends Genet,2022,38(6):598-612.
11 王蓉,潘思思,宋霞.晚期非小细胞肺癌EGFR-TP53共突变的研究进展[J].中国肺癌杂志,2022,25(3):174-182.
12 Passaro A,Attili I,Rappa A,et al.Genomic characterization of concurrent alterations in non-small cell lung cancer(NSCLC)harboring actionable mutations[J].Cancers(Basel),2021,13(9):2172.
13 Fu J,Tong Y,Xu Z,et al.Impact of TP53 mutations on EGFR-tyrosine kinase inhibitor efficacy and potential treatment strategy[J].Clin Lung Cancer,2023,24(1):29-39.
14 Canale M,Petracci E,Delmonte A,et al.Impact of TP53 mutations on outcome in EGFR-mutated patients treated with first-line tyrosine kinase inhibitors[J].Clin Cancer Res,2017,23(9):2195-2202.
15 Lan B,Zhao N,Du K,et al.Concurrent TP53 mutations predict a poor prognosis of EGFR-mutant NSCLCs treated with TKIs:an updated systematic review and meta-analysis[J].Oncol Lett,2022,24(5):384.
16 Li XM,Li WF,Lin JT,et al.Predictive and prognostic potential of TP53 in patients with advanced non-small-cell lung cancer treated with EGFR-TKI:analysis of a phase III randomized clinical trial(CTONG 0901)[J].Clin Lung Cancer,2021,22(2):100-109.
17 Yu R,Bai H,Li T,et al.TP53 mutations in circulating tumor DNA in advanced epidermal growth factor receptor-mutant lung adenocarcinoma patients treated with gefitinib[J].Transl Oncol,2021,14(9):101163.
18 Le X,Molife C,Leusch MS,et al.TP53 co-mutation status association with clinical outcomes in patients with EGFR-mutant non-small cell lung cancer[J].Cancers(Basel),2022,14(24):6127.
19 Zhang C,Liu J,Xu D,et al.Gain-of-function mutant p53 in cancer progression and therapy[J].J Mol Cell Biol,2020,12(9):674-687.
20 Rho JK,Choi YJ,Ryoo BY,et al.P53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer[J].Cancer Res,2007,67(3):1163-1169.
21 Offin M,Chan JM,Tenet M,et al.Concurrent RB1 and TP53 alterations define a subset of EGFR-mutant lung cancers at risk for histologic transformation and inferior clinical outcomes[J].J Thorac Oncol,2019,14(10):1784-1793.
22 Zheng C,Li X,Ren Y,et al.Coexisting EGFR and TP53 mutations in lung adenocarcinoma patients are associated with COMP and ITGB8 upregulation and poor prognosis[J].Front Mol Biosci,2020,7:30.
23 Vokes NI,Chambers E,Nguyen T,et al.Concurrent TP53 mutations facilitate resistance evolution in EGFR-mutant lung adenocarcinoma[J].J Thorac Oncol,2022,17(6):779-792.
24 Lopes-Coelho F,Martins F,Pereira SA,et al.Anti-angiogenic therapy:current challenges and future perspectives[J].Int J Mol Sci,2021,22(7):3765.
25 Li Y,Lin M,Wang S,et al.Novel angiogenic regulators and anti-angiogenesis drugs targeting angiogenesis signaling pathways:perspectives for targeting angiogenesis in lung cancer[J].Front Oncol,2022,12:842960.
26 Schwaederlé M,Lazar V,Validire P,et al.VEGF-A expression correlates with TP53 mutations in non-small cell lung cancer:implications for antiangiogenesis therapy[J].Cancer Res,2015,75(7):1187-1190.
27 Wheler JJ,Janku F,Naing A,et al.TP53 alterations correlate with response to VEGF/VEGFR inhibitors:implications for targeted therapeutics[J].Mol Cancer Ther,2016,15(10):2475-2485.
28 Fang S,Cheng W,Zhang M,et al.Association of TP53 mutations with response to anlotinib treatment in advanced Non-Small Cell lung cancer[J].Onco Targets Ther,2020,13:6645-6650.
29 Cheng Y,Ma L,Liu Y,et al.Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors[J].Lung Cancer,2020,145:63-70.
30 Sun H,Ren P,Chen Y,et al.Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer:a real-world study[J].BMC Cancer,2023,23(1):198.
31 Nakagawa K,Nadal E,Garon EB,et al.RELAY subgroup analyses by EGFR Ex19del and Ex21L858R mutations for ramucirumab plus erlotinib in metastatic non-small cell lung cancer[J].Clin Cancer Res,2021,27(19):5258-5271.
32 Zhao H,Yao W,Min X,et al.Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant NSCLC:the phase III ACTIVE study(CTONG1706)[J].J Thorac Oncol,2021,16(9):1533-1546.
33 商凯.EGFR-TKIs联合化疗一线治疗EGFR/TP53基因共突变晚期NSCLC的疗效及安全性观察[D].南昌:南昌大学,2022.
34 Yang Z,Chen Y,Wang Y,et al.Efficacy of EGFR-TKI plus chemotherapy or monotherapy as first-line treatment for advanced EGFR-mutant lung adenocarcinoma patients with co-mutations[J].Front Oncol,2021,11:681429.
35 Liu S,Geng S,Shi N,et al.Survival prediction of patients treated with immune checkpoint inhibitors via KRAS/TP53/EGFR-single gene mutation[J].Front Pharmacol,2022,13:878540.
36 Jin Y,Xue Q,Shen X,et al.PD-L1 expression and comprehensive molecular profiling predict survival in non-small cell lung cancer:a real-world study of a large chinese cohort[J].Clin Lung Cancer,2022,23(1):43-51.
37 Assoun S,Theou-Anton N,Nguenang M,et al.Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer[J].Lung Cancer,2019,132:65-71.
38 Lin X,Wang L,Xie X,et al.Prognostic biomarker TP53 mutations for immune checkpoint blockade therapy and its association with tumor microenvironment of lung adenocarcinoma[J].Front Mol Biosci,2020,7:602328.
39 Wang S,Xie T,Wang Y,et al.166P Integrated analysis reveals TP53 mutation as a biomarker of anti-PD-1/PD-L1 treatment for epidermal growth factor receptor(EGFR)-mutant lung adenocarcinoma patients[J].Ann Oncol,2022,33:S108.
40 Oxnard GR,Yang JC,Yu H,et al.TATTON:a multi-arm,phase Ib trial of osimertinib combined with selumetinib,savolitinib,or durvalumab in EGFR-mutant lung cancer[J].Ann Oncol,2020,31(4)507-516.
41 Chen Y,Chen Z,Chen R,et al.Immunotherapy-based combination strategies for treatment of EGFR-TKI-resistant non-small-cell lung cancer[J].Future Oncol,2022,18(14):1757-1775.

[1]	张庆怀, 韩阿蒙, 杨森, 李秀梅, 赵健鑫, 张彦秋. 乳腺癌患者保乳术后五种放疗技术的疗效比较研究[J]. 实用肿瘤学杂志, 2023, 37(3): 224-229.
[2]	崔永康, 于承平, 许浩志, 马新宇, 麻勇, 李林强. 营养风险指数在可切除肝细胞癌患者术后并发症及预后预测中的作用[J]. 实用肿瘤学杂志, 2023, 37(3): 243-251.
[3]	徐婷, 程华, 张维. 老年胰腺癌早期诊断及微创外科治疗的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 257-261.
[4]	伦立鑫, 钟振滨, 赵新宇, 吴筹, 郝春成. 抗EGFR治疗在头颈部鳞癌中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 276-280.
[5]	殷鼎威, 井杰. 肠道菌群在肝细胞癌中的作用及治疗应用的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 281-286.
[6]	龙朝恋, 李琨, 刘子臣, 张娜娜, 车南颖. 非小细胞肺癌程序性死亡配体-1表达与临床病理特征和常见驱动基因变异的相关性研究[J]. 实用肿瘤学杂志, 2023, 37(2): 117-122.
[7]	王丙萍, 段金凯, 张双, 高艳伟, 任猛, 陈良全, 高维实. NK细胞联合PD-1单抗杀伤结直肠癌细胞的研究[J]. 实用肿瘤学杂志, 2023, 37(2): 130-136.
[8]	李路桥, 邹征云. 恶性黑色素瘤免疫治疗超进展研究现状[J]. 实用肿瘤学杂志, 2023, 37(2): 144-148.
[9]	张一丹, 钟锐, 孙振轩, 王腾, 刘金涛. SYT13在癌症中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(2): 181-184.
[10]	文世超, 王静萱. 铜依赖性细胞死亡及铜在乳腺癌治疗中的研究现状[J]. 实用肿瘤学杂志, 2023, 37(2): 185-189.
[11]	夏前林, 仇荣, 陆悦, 张琼, 杜玉珍. 肺腺癌m6A甲基化调控因子相关预后风险模型的构建及临床意义[J]. 实用肿瘤学杂志, 2023, 37(1): 39-45.
[12]	王嘉倍, 张运广, 刘连新. 免疫治疗联合分子靶向药物治疗中晚期肝细胞癌的临床疗效及安全性分析:一项单臂回顾性研究[J]. 实用肿瘤学杂志, 2022, 36(6): 489-494.
[13]	杨菊, 刘芹, 刘宝瑞, 魏嘉. 胃癌相关癌睾抗原筛选与免疫浸润分析[J]. 实用肿瘤学杂志, 2022, 36(6): 495-501.
[14]	巩芮宁, 任贺. 胰腺导管腺癌免疫治疗研究现状和展望[J]. 实用肿瘤学杂志, 2022, 36(6): 502-506.
[15]	曹文杰, 魏瑗, 邝栋明. 肿瘤浸润B细胞与免疫治疗[J]. 实用肿瘤学杂志, 2022, 36(6): 507-512.